ARTICLE | Company News

Canbridge licenses Chinese rights to Puma's Nerlynx

February 2, 2018 12:44 AM UTC

Puma Biotechnology Inc. (NASDAQ:PBYI) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to develop and commercialize cancer drug Nerlynx neratinib in China, including Hong Kong and Macau, and Taiwan.

Puma markets Nerlynx in the U.S. for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy...